[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Seres Therapeutics Inc (MCRB)

Seres Therapeutics Inc (MCRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,172
  • Shares Outstanding, K 9,586
  • Annual Sales, $ 790 K
  • Annual Income, $ 5,700 K
  • EBIT $ -94 M
  • EBITDA $ -90 M
  • 60-Month Beta 0.26
  • Price/Sales 98.41
  • Price/Cash Flow 7.46
  • Price/Book 1.66

Options Overview Details

View History
  • Implied Volatility 151.95% (+7.60%)
  • Historical Volatility 64.66%
  • IV Percentile 69%
  • IV Rank 42.93%
  • IV High 243.13% on 03/12/26
  • IV Low 83.37% on 01/21/26
  • Expected Move (DTE 16) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 60
  • Volume Avg (30-Day) 16
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 4,121
  • Open Int (30-Day) 5,548
  • Expected Range 7.09 to 7.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-2.24
  • Growth Rate Est. (year over year) +44,698.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.98 +1.58%
on 04/28/26
9.55 -25.77%
on 03/30/26
-1.91 (-21.22%)
since 03/27/26
3-Month
6.98 +1.58%
on 04/28/26
16.11 -56.00%
on 02/02/26
-8.05 (-53.17%)
since 01/28/26
52-Week
6.53 +8.58%
on 05/15/25
29.98 -76.35%
on 11/20/25
-2.22 (-23.85%)
since 04/28/25

Most Recent Stories

More News
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration Additional presentations underscore the role of live...

MCRB : 7.09 (-3.14%)
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration Additional presentations underscore the role of live...

MCRB : 7.09 (-3.14%)
Seres Therapeutics to Present at CARB-X Investor Day

CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at the...

MCRB : 7.09 (-3.14%)
Seres Therapeutics: Q4 Earnings Snapshot

Seres Therapeutics: Q4 Earnings Snapshot

MCRB : 7.09 (-3.14%)
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track for...

MCRB : 7.09 (-3.14%)
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates

Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs...

MCRB : 7.09 (-3.14%)
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases

Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activities...

MCRB : 7.09 (-3.14%)
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowstâ„¢ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy

Data demonstrate  clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx ® platform provides high-resolution functional biological understanding...

MCRB : 7.09 (-3.14%)
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside chat...

MCRB : 7.09 (-3.14%)
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant...

MCRB : 7.09 (-3.14%)

Business Summary

Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 8.32
2nd Resistance Point 8.03
1st Resistance Point 7.56
Last Price 7.09
1st Support Level 6.80
2nd Support Level 6.51
3rd Support Level 6.04

See More

52-Week High 29.98
Fibonacci 61.8% 21.02
Fibonacci 50% 18.25
Fibonacci 38.2% 15.49
Last Price 7.09
52-Week Low 6.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.